🔗 Share this article

As America undertakes unprecedented adjustments to its vaccination schedules, one figure has surfaced unexpectedly: Dr. Tracy Beth Høeg, a US-based sports medicine doctor and epidemiologist who initially gained attention by casting doubt on Covid vaccines during the global health crisis and has concentrated on possible fatalities following COVID-19 vaccination in her recent position at the US Food and Drug Administration (FDA).

Scheduled Overhauls to Pediatric Vaccine Schedule

Public health authorities planned to announce radical revisions to the pediatric vaccination calendar earlier this month, aligning the US with Denmark’s vaccine program, sources say – a substantial departure that would place the US out of alignment with much of the global community with little proof for public health gain. The announcement has been delayed until the new year.

Rather than Vinay Prasad, Dr. Høeg is set to address the audience at the meeting. She was newly appointed temporary leader of the FDA’s CDER, the fifth appointee to head the division this calendar year.

A New Direction at the FDA

Høeg's temporary position may indicate a closer partnership between the drug and vaccine centers as Dr. Høeg and Dr. Prasad solidify control at the agency – and it signals a greater focus upon dismantling previously authorized immunizations at the FDA.

Dr. Høeg has repeatedly called for ending certain pediatric vaccine recommendations in the US in order to be more similar to Denmark, a society with nationalized medicine and a citizenry roughly the population of Wisconsin’s.

To date public appearances, she has continued to focus on vaccination policy – usually the domain of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of drug regulation.

Questions Over Expertise

Høeg has no apparent track record in drug development, approval processes or leadership, which has been customary for past leaders of the biologics center. She has served at the FDA as a top consultant to the FDA chief and CBER since spring.

“It seems she lacks to have the requisite experience” for leading the pharmaceutical oversight division, remarked Dr. Jonathan Howard. “She’s never run a scientific study. She is not versed in running a sizeable institution. She has no expertise in pharmaceutical oversight.”

Past heads of the center would “understand regulatory frameworks and the research of medication creation”, noted Dr. Janet Woodcock. “Objectively, she has not acquired the type of experience that prior appointees who headed CBER have had.”

This division has an enormous portfolio at the agency, Woodcock stated.

“Many people just pays attention on the innovative therapies, but the generic program authorizes a multitude of generic medications. There is also a biosimilars program, OTC medication office and so forth, and every single one have to be managed,” Woodcock said. “The responsibility you neglect, that’s the thing that I always told people is going to cause problems.”

There is also, a major leadership aspect to the role, which supervises over 5,000 employees. “It’s a huge management job, if you execute it properly,” Woodcock said.

Response and Contentious Initiatives

In response to questions about Høeg’s credentials and whether this selection signifies greater collaboration among FDA leaders on immunizations, a spokesperson said that the “questions are based on incorrect presumptions”.

“Her resume matches the responsibilities of her position,” the representative said, pointing to the time Dr. Høeg spent advising the FDA commissioner on “pharmaceutical safety and oversight research, including computational safety modeling and vaccine surveillance”.

As the temporary head, Dr. Høeg takes over the commissioner’s recently launched expedited review system, a contentious rapid medication authorization process that apparently troubled her former heads. “By what process are these therapies being picked for this expedited pathway? Who takes the choices?” Howard asked. “There’s a lot of confidentiality going on at the regulatory body right now.”

In general, he stated, “the FDA seems to be moving towards more relaxed regulations of all drugs, except for shots.”

Established Track Record on Vaccines

Regarding immunizations, Dr. Høeg has a more established, if concerning, past, Howard said. She authored a analysis using unverified volunteer-provided data to determine the incidence of myocarditis following Covid immunization. She consulted for the Florida surgeon general Dr. Joseph Ladapo, who reportedly have modified findings to suggest COVID-19 vaccines are more dangerous than they are.

Included in her “desired changes” for the current administration featured revising rules for novel immunizations and discontinuing “unnecessary” immunizations, she remarked after the election on a online show. At the agency, Dr. Høeg has reportedly suggested excluding teenage boys from obtaining COVID-19 vaccinations.

“She’s an all-around ideologue who commences with her conclusions and works backwards to retrofit the science in a highly misleading, untruthful manner,” Howard argued.

Consolidating Power and a “Revenge Tour”

Dr. Høeg aligned with fellow dissenters, {like|